Ipsen Gives Genfit Liver Drug New Lease Of Life
Pays €120m Upfront For Elafibranor Rights
Executive Summary
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.
You may also be interested in...
Ipsen Eyes Opportunity In Rare Liver Diseases With Albireo Buy
The French firm is paying a 104% premium plus contingent value rights of an additional $10 per share to get hold of AstraZeneca spin-off Albireo and its lead asset Bylvay, which is approved for progressive familial intrahepatic cholestasis and is showing promise in two other more lucrative indications.
Genfit Pivots To Opposite End Of The Liver Disease Spectrum
Genfit CEO Pascal Prigent talks to Scrip about the company's high-profile trial failure in NASH and the pipeline pivot to various other drug candidates for rare liver diseases.
Genfit To Pick Up Second Liver Failure Candidate In €40m Versantis Buyout
Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.